Sol-Gel Technologies SLGL
NASDAQ SLGL
$69.96 -0.14 (-0.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Net Income towards Common Stockholders of $3.7 million for Q1 2026, down 57.69% year-over-year from $8.8 million in Q1 2025, and up 106.02% quarter-over-quarter from -$61.9 million in Q4 2025.

Analysis

Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Net Income towards Common Stockholders for 10 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 57.69% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at -$64.5 million (down 34.58% YoY), while the FY2025 annual figure was -$66.0 million, down 6.86% from the prior year.
  • Net Income towards Common Stockholders advanced to $3.7 million in Q1 2026 per SLGL's latest filing, from -$61.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $10.7 million in Q1 2023 and bottomed at -$61.9 million in Q4 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$8.8 million across 5 years, with a median of $0.01 in 2022.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 2100.0% in 2023 and fell as far as 21327599900.0% in 2023.
  • Sol-Gel Technologies' Net Income towards Common Stockholders stood at -$0.25 in 2022, then tumbled by 21327599900.0% to -$53.3 million in 2023, then declined by 4.82% to -$55.9 million in 2024, then fell by 10.78% to -$61.9 million in 2025, then surged by 106.02% to $3.7 million in 2026.
  • Business Quant data shows SLGL's Net Income towards Common Stockholders at $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Sol-Gel Technologies 194.01 Mn 146.08 Mn - -4.64 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.64 Mn
Mar 31, 2026 3.86 Mn
Dec 31, 2025 -3.41 Mn
Sep 30, 2025 -6.29 Mn
Jun 30, 2025 10.85 Mn
Mar 31, 2025 9.07 Mn
Dec 31, 2024 -6.10 Mn
Sep 30, 2024 -828,000.00
Jun 30, 2024 1.27 Mn
Mar 31, 2024 6.71 Mn
Dec 31, 2023 -5.41 Mn
Sep 30, 2023 -6.31 Mn
Jun 30, 2023 -7.08 Mn
Mar 31, 2023 11.06 Mn
Dec 31, 2022 -6.21 Mn
Sep 30, 2022 -3.63 Mn
Jun 30, 2022 134,000.00
Mar 31, 2022 5.95 Mn
Dec 31, 2021 13.96 Mn
Sep 30, 2021 1.27 Mn